Insider Transactions in Q3 2022 at Theravance Biopharma, Inc. (TBPH)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 16
2022
|
Glaxosmithkline PLC |
SELL
Other acquisition or disposition
|
Indirect |
9,644,807
-100.0%
|
$86,803,263
$9.75 P/Share
|
|
Aug 19
2022
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,804
-1.1%
|
$142,236
$9.34 P/Share
|
|
Aug 19
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
25,676
-5.14%
|
$231,084
$9.34 P/Share
|
|
Aug 19
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Direct |
18,991
-5.21%
|
$170,919
$9.34 P/Share
|
|
Aug 19
2022
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
10,413
-3.16%
|
$93,717
$9.34 P/Share
|
|
Aug 16
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
4,906
-1.33%
|
$44,154
$9.71 P/Share
|
|
Aug 09
2022
|
Richard A Graham SVP, RESEARCH & DEVELOPMENT |
SELL
Open market or private sale
|
Direct |
15,086
-3.92%
|
$120,688
$8.79 P/Share
|
|
Jul 25
2022
|
Andrew A. Hindman SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+3.85%
|
-
|